Key Finding
Six efferocytosis-related genes (ANXA1, PANX1, ANXA5, CD93, SERPINE1, MFGE8) were identified as biomarkers that predict clinical response to ustekinumab treatment in ulcerative colitis patients.
Researchers investigated how the body clears dead cells in ulcerative colitis (UC), a chronic inflammatory bowel condition, and whether this process affects how well patients respond to ustekinumab (UST), a common biologic medication. Using advanced genetic analysis, scientists studied tissue samples from UC patients and examined how immune cells, particularly macrophages, remove dead cells through a process called efferocytosis. They discovered that when this cleanup process is impaired, inflammation worsens. The study identified six specific genes (ANXA1, PANX1, ANXA5, CD93, SERPINE1, MFGE8) that play crucial roles in this cellular cleanup and found these genes could predict which patients would respond better to ustekinumab treatment. Macrophages with M2 characteristics showed the best ability to clear dead cells and reduce inflammation. While this research doesn't directly involve acupuncture, it reveals important mechanisms of intestinal inflammation that may be relevant to complementary care approaches. Acupuncture has been explored as a supportive therapy for inflammatory bowel diseases, potentially helping manage symptoms and support immune balance. Understanding these cellular mechanisms could help practitioners better integrate acupuncture with conventional treatments, particularly for patients on biologic medications. Future research might explore whether acupuncture influences efferocytosis pathways or macrophage function in UC patients. If you have ulcerative colitis and are considering acupuncture as part of your care plan, consult a licensed acupuncturist experienced in treating digestive disorders.
This multi-omics study integrated single-cell and bulk transcriptomic data from human UC colonic mucosa to characterize efferocytosis dysfunction. Using machine learning algorithms, researchers identified six hub genes (ANXA1, PANX1, ANXA5, CD93, SERPINE1, MFGE8) associated with UC progression and ustekinumab (UST) therapeutic response. Analysis revealed cellular heterogeneity in efferocytosis stages: "eat me" and "digest me" signaling upregulated in myeloid cells, while "find me" signaling activated in stromal cells. M2-polarized macrophages demonstrated enhanced phagocytic capacity for apoptotic cell clearance. Molecular docking analysis showed strong binding affinities between hub gene-encoded proteins and UST. Mouse model validation confirmed dysregulated expression via transcriptomic and proteomic analyses. Clinical takeaway: Efferocytosis-related biomarkers may predict biologic therapy response, suggesting macrophage-targeted interventions could enhance mucosal healing. While this research focuses on pharmaceutical mechanisms, understanding immune regulation pathways may inform integrative approaches to IBD management, including potential synergies between conventional biologics and complementary modalities.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
📌 Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
📌 Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.